The Fort Worth Press - SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

USD -
AED 3.673008
AFN 64.503214
ALL 80.819685
AMD 361.405228
ANG 1.789785
AOA 917.000132
ARS 1525.743205
AUD 1.42204
AWG 1.80125
AZN 1.694926
BAM 1.741787
BBD 2.015015
BDT 123.745402
BGN 1.747831
BHD 0.377604
BIF 3000.997453
BMD 1
BND 1.278059
BOB 11.730759
BRL 5.0336
BSD 1.000472
BTN 94.559477
BWP 13.70595
BYN 2.971479
BYR 19600
BZD 2.012094
CAD 1.40468
CDF 2315.999614
CHF 0.823985
CLF 0.02484
CLP 977.639757
CNY 6.67805
CNH 6.673855
COP 3194.48
CRC 455.529135
CUC 1
CUP 24.010794
CVE 98.199695
CZK 21.58565
DJF 177.720049
DKK 6.651515
DOP 61.440772
DZD 134.600855
EGP 54.383604
ERN 15
ETB 163.87083
EUR 0.88984
FJD 2.253797
FKP 0.747587
GBP 0.74635
GEL 2.589651
GGP 0.747587
GHS 11.660299
GIP 0.747587
GMD 73.49688
GNF 8854.987666
GTQ 7.645587
GYD 209.311853
HKD 7.846885
HNL 26.857072
HRK 6.703799
HTG 131.084908
HUF 325.065498
IDR 18027.05
ILS 3.088402
IMP 0.747587
INR 94.43255
IQD 1516.6493
IRR 1832374.999738
ISK 121.269746
JEP 0.747587
JMD 158.780625
JOD 0.709015
JPY 158.134988
KES 129.859579
KGS 87.449845
KHR 4068.146802
KMF 439.503571
KPW 899.999961
KRW 1325.979763
KWD 0.31018
KYD 0.833753
KZT 446.890557
LAK 22518.390538
LBP 89591.044298
LKR 332.14739
LRD 170.580744
LSL 16.412051
LTL 2.95274
LVL 0.60489
LYD 6.419294
MAD 9.819615
MDL 17.998442
MGA 4521.489767
MKD 54.903951
MMK 2099.21541
MNT 3597.533576
MOP 8.085932
MRU 40.128421
MUR 47.319959
MVR 15.459751
MWK 1734.751129
MXN 18.645615
MYR 4.081198
MZN 63.902977
NAD 16.412051
NGN 1331.830194
NIO 36.816372
NOK 9.371645
NPR 151.295341
NZD 1.75332
OMR 0.384501
PAB 1.000481
PEN 3.438421
PGK 4.479652
PHP 63.399499
PKR 276.89823
PLN 3.87625
PYG 5756.677086
QAR 3.647261
RON 4.753003
RSD 104.53802
RUB 82.104013
RWF 1478.615162
SAR 3.748965
SBD 8.07458
SCR 13.97401
SDG 601.492558
SEK 9.878845
SGD 1.27707
SHP 0.7473
SLE 23.919966
SLL 20969.504398
SOS 571.749178
SRD 37.735499
STD 20697.981008
STN 21.819089
SVC 8.754392
SYP 13001.999685
SZL 16.418788
THB 33.570497
TJS 9.214157
TMT 3.51
TND 2.986543
TOP 2.40776
TRY 49.598465
TTD 6.792416
TWD 32.411301
TZS 2644.999678
UAH 45.047334
UGX 4207.076509
UYU 40.164934
UZS 11975.562621
VES 879.788897
VND 25856.5
VUV 119.136032
WST 2.774679
XAF 583.696876
XAG 0.017313
XAU 0.000241628771
XCD 2.70255
XCG 1.803058
XDR 0.707052
XOF 583.696876
XPF 106.20998
YER 236.101147
ZAR 16.360597
ZMK 9001.202969
ZMW 20.069287
ZWL 321.999592
SSP 5787.554334
MXV 2.10465
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks
SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

SMX Brings Identity to Cannabis and rPET Under FDA-Compliant Frameworks

NEW YORK, NY / ACCESS Newswire / December 19, 2025 / Cannabis is entering a phase where identity matters more than narrative. As federal oversight takes shape, the industry is being pulled out of a patchwork of state systems and into a framework that resembles other regulated categories. In those environments, compliance is not about disclosure. It is about proof.

Text size:

That shift changes what it means to operate at scale.

Federal normalization does not immediately transform cannabis into a pharmaceutical, but it does move it closer to medical-grade expectations. Products that are ingested, absorbed, or used therapeutically are judged by how well their physical reality aligns with their records. Labels, declarations, and after-the-fact reporting are no longer sufficient. Regulators expect continuity between what a product is and what the system says it is.

This is where identity becomes infrastructure. Here's why it's vital to this conversation.

Cannabis Needs Verification, Not Visibility

Most cannabis compliance systems were built for speed and local reporting. They track activity, but they do not always verify integrity. Under light oversight, that distinction is tolerable. Under federal scrutiny, it becomes a liability.

Federal regulators expect records that hold up over time. They expect chain-of-custody continuity from origin through distribution. They expect discrepancies to be explainable without reconstruction. When systems rely on manual reconciliation or fragmented data, those expectations are difficult to meet.

SMX (NASDAQ:SMX) approaches this problem at the material level. Instead of relying solely on databases or documentation, its technology embeds identity directly into physical materials. That identity persists through transformation and movement, allowing records to reflect reality rather than attempt to approximate it.

For cannabis, that approach aligns naturally with the direction of federal oversight. When proof is embedded, compliance becomes continuous instead of episodic.

FDA-Compliant RPET Shows The Model Works

This same logic is already operating inside FDA-regulated markets.

SMX recently demonstrated its molecular marking technology in recycled PET plastics used for food-contact applications, operating within FDA Food Contact Substance regulations under 21 CFR. These rules govern some of the most tightly controlled materials in the supply chain. Any system that functions here must demonstrate stability, safety, and verifiable compliance.

In practice, molecular markers allow recycled material to carry permanent, invisible proof of origin, composition, and regulatory status, even in applications where contamination risk is tightly controlled. This enables recycled plastics to move into categories that were previously closed to them.

That matters for cannabis because the regulatory expectation is similar. When a product interacts with the human body, regulators care less about intent and more about verifiable control. Food-grade rPET provides a real-world demonstration that molecular identity can operate inside strict federal frameworks.

From Cannabis To Plastics, The Compliance Logic Is Shared

Cannabis and rPET are different markets, but they face the same regulatory logic. Both require traceability that survives transformation. Both demand proof that cannot be altered downstream. Both expose the weaknesses of systems built on declarations.

SMX's relevance is not tied to a single product category. It is tied to the need for persistent identity in regulated environments. Whether the material is plant-based or polymer-based, the requirement is the same. Physical goods must be able to prove what they are.

As cannabis moves toward federal standards, that requirement becomes unavoidable.

Identity Becomes The Foundation Of Scale

Markets are no longer rewarding speed alone. They are rewarding control.

SMX's ability to embed identity at the molecular level and to operate within FDA-compliant frameworks positions it at the intersection of regulation and scalability. Cannabis operators moving into federal oversight face the same decision that plastics manufacturers already confront. Patch legacy systems, or adopt infrastructure built for verification.

As oversight tightens, the difference becomes decisive.

Cannabis will not be filtered by enthusiasm or branding. It will be filtered by execution. The companies that can prove integrity across their supply chains will advance. Those who cannot will face compounding friction.

Identity is no longer a feature. It is the foundation.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This information contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, forecasts, and assumptions regarding future events involving SMX (NASDAQ: SMX), its technologies, its partnership activities, and its development of molecular marking systems for recycled PET and other materials. Forward looking statements are not historical facts. They involve risks, uncertainties, and factors that may cause actual results to differ materially from those expressed or implied.

Forward looking statements in this editorial include, but are not limited to, expectations regarding the integration of SMX's molecular markers into U.S. recycling markets; the potential for FDA-compliant markers to enable recycled PET to enter food-grade and other regulated applications; the scalability of SMX solutions across diverse global supply chains; anticipated adoption of identity-based verification systems by manufacturers, recyclers, regulators, or brand owners; the potential economic impact of turning recycled plastics into tradeable or monetizable assets; the expected performance of SMX's Plastic Cycle Token or other digital verification instruments; and the belief that molecular-level authentication may influence pricing, compliance, sustainability reporting, or financial strategies used within the plastics sector.

These forward looking statements are also subject to assumptions regarding regulatory developments; market demand for authenticated recycled content; the pace of corporate adoption of traceability technology; global economic conditions; supply chain constraints; evolving environmental policies; and general industry behavior relating to sustainability commitments and recycling mandates. Risks include, but are not limited to, changes in FDA or international regulatory standards; technological challenges in large-scale deployment of molecular markers; competitive innovations from other companies; operational disruptions in recycling or plastics manufacturing; fluctuations in pricing for virgin or recycled plastics; and the broader economic conditions that influence capital investment and industrial activity.

Detailed risk factors are described in SMX's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward looking statements. These statements speak only as of the date of publication. SMX undertakes no obligation to update or revise forward looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

EMAIL: [email protected]

SOURCE: SMX (Security Matters) Public Limited



View the original press release on ACCESS Newswire

S.Rocha--TFWP